

WCG PharmaSeek's Impact on Study Start-up Reduction for a COVID-19 Study

WCG PharmaSeek Objectives

- Accelerate study start-up for a COVID-19 trial
- Leverage existing relationships with sponsor, CRO, and sites to get budget and CTA finalized quickly and effectively

Impact on Study Start-up Timelines

Sponsor CTA & Budget

- Leveraged existing relationship with sites to agree to a single budget and contract template to ensure expedited study start-up
- Budget agreed to in **2** business days and CTA agreed to in **5** business days

Site Contracting

- Site #1 – Finalized same day, fully-executed in **2** business days
- Site #2 – Finalized in **1** business day, fully-executed in **4** business days
- Site #3 – Finalized in **3** business day, fully-executed in **4** business days
- Site #4 – Finalized in **2** business days, fully-executed in **7** business days

93%

Reduction in Contract/Budget Negotiation Timelines Compared to Industry Average¹

1-Tufts CSDD Impact Report, March/April 2018

Study Start-up Outcomes

- Deployed key study start-up services to 4 sites in 1.4 business day, fully-executed in 4.2 business days

Sites Available for Your COVID-19 Study

- There are currently 39 WCG PharmaSeek Network sites that are interested in participating in COVID-19 outpatient treatments, 73 sites interested in participating in COVID-19 vaccine trials, and 3 hospital sites interested in COVID-19 treatments. By working with WCG PharmaSeek, we can directly connect you to these interested sites for your trials.

Interested in learning more about how WCG PharmaSeek can help you reduce study start-up timelines for your COVID-19 trials? Contact below